Vivos receives Nasdaq minimum bid price deficiency notice; has 180 days to cure
Vivos Therapeutics received a notice on June 5, 2026 from Nasdaq indicating noncompliance with the minimum closing bid price requirement of $1.00 per share…
$1.00$2.4M180-calendar-day